WO2024038307 - DOSING REGIMENS FOR SARS-COV-2 BINDING MOLECULES
National phase entry is expected:
Publication Number
WO/2024/038307
Publication Date
22.02.2024
International Application No.
PCT/IB2022/057822
International Filing Date
20.08.2022
Title **
[English]
DOSING REGIMENS FOR SARS-COV-2 BINDING MOLECULES
[French]
SCHÉMAS POSOLOGIQUES POUR MOLÉCULES DE LIAISON AU SARS-COV-2
Applicants **
NOVARTIS AG
MOLECULAR PARTNERS AG
Inventors
CLAAS, Allison
KNUTSON, Charles Gerhard Francesco
STUMPP, Michael Tobias
WALSER, Marcel
ZITT, Christof
Priority Data
63/373,031
19.08.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2171 | |
| EPO | Filing, Examination, Granting | 10260 | |
| Japan | Filing, Examination, Granting | 2279 | |
| South Korea | Filing, Examination, Granting | 2323 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,773
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The instant disclosure relates to compositions comprising SARS-CoV-2 binding molecules and methods of use thereof. Provided herein are dosing regimens for administration of SARS-CoV-2 binding molecules, including the DARPin® protein ensovibep.[French]
La présente invention concerne des compositions comprenant des molécules de liaison au SARS-CoV-2 et des procédés d'utilisation de celles-ci. L'invention concerne également des schémas posologiques pour l'administration de molécules de liaison au SARS-CoV-2, comprenant l'ensovibep à protéine DARPin®.